80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]王振河,姜德謙,許丹焰,等.可溶性環(huán)氧化物水解酶抑制劑對(duì)小鼠內(nèi)皮祖細(xì)胞分泌血管內(nèi)皮生長(zhǎng)因子及缺氧誘導(dǎo)因子-1α的促進(jìn)作用[J].福建醫(yī)藥雜志,2021,43(04):128-132.
　WANG Zhenhe,JIANG Deqian,XU Danyan,et al.Effects of soluble epoxide hydrolase inhibitors on secretion of vascular endothelial growth factor and hypoxia-inducible factor-1α by murine endothelial progenitor cells[J].FUJIAN MEDICAL JOURNAL,2021,43(04):128-132.
點(diǎn)擊復(fù)制

可溶性環(huán)氧化物水解酶抑制劑對(duì)小鼠內(nèi)皮祖細(xì)胞分泌血管內(nèi)皮生長(zhǎng)因子及缺氧誘導(dǎo)因子-1α的促進(jìn)作用()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
43
期數(shù):
2021年04期
頁(yè)碼:
128-132
欄目:
基礎(chǔ)研究
出版日期:
2021-08-15

文章信息/Info

Title:
Effects of soluble epoxide hydrolase inhibitors on secretion of vascular endothelial growth factor and hypoxia-inducible factor-1α by murine endothelial progenitor cells
文章編號(hào):
1002-2600(2021)04-0128-05
作者:
王振河; 姜德謙1; 許丹焰1; 李衛(wèi)華; 謝強(qiáng)
廈門(mén)大學(xué)附屬第一醫(yī)院心內(nèi)科（廈門(mén) 361003）
Author(s):
WANG Zhenhe;  JIANG Deqian;  XU Danyan;  LI Weihua;  XIE Qiang
Department of Cardiology, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, China
關(guān)鍵詞:
可溶性環(huán)氧化物水解酶抑制劑; t-AUCB; 過(guò)氧化體增殖物激活型受體γ; 血管內(nèi)皮生長(zhǎng)因子; 缺氧誘導(dǎo)因子-1α; 內(nèi)皮祖細(xì)胞
Keywords:
soluble epoxide hydrolase inhibitor; t-AUCB; catalosome proliferator-activated receptor γ; vascular endothelial growth factor; hypoxia-inducible factor-1α; endothelial progenitor cell
分類(lèi)號(hào):
R363
文獻(xiàn)標(biāo)志碼:
A
摘要:
目的 探討可溶性環(huán)氧化物水解酶抑制劑（t-AUCB）能否促進(jìn)小鼠來(lái)源內(nèi)皮祖細(xì)胞（EPCs）分泌內(nèi)皮生長(zhǎng)因子（VEGF）和缺氧誘導(dǎo)因子-1α（HIF-1α），及可能的相關(guān)機(jī)制。 方法 提取小鼠長(zhǎng)骨骨髓，離心分離培養(yǎng)，取得高純度EPCs，不同濃度可溶性環(huán)氧化物水解酶抑制劑（t-AUCB）和過(guò)氧化體增殖物激活型受體γ（PPAR-γ）阻斷劑GW9662單獨(dú)或聯(lián)合干預(yù)EPCs，Western blot檢測(cè)上述EPCs體外分泌VEGF及HIF-1α情況。結(jié)果從0～100 μmol/L，t-AUCB呈濃度依賴(lài)性增強(qiáng)EPCs體外分泌VEGF、HIF-1α能力，而5 μmol/L t-AUCB阻斷劑GW9662可抑制EPC上述功能。1、10、50、100 μmol/L t-AUCB促進(jìn)EPCs分泌VEGF、HIF-1α能力與0 μmol/L t-AUCB相比，差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）；GW9662+100 μmol/L t-AUCB與100 μmol/L t-AUCB比較，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05），與0 μmol/L t-AUCB比較，差異也具有統(tǒng)計(jì)學(xué)意義（P<0.05）。 結(jié)論 t-AUCB可促進(jìn)EPCs分泌VEGF及HIF-1α，其機(jī)制可能與激活PPAR-γ通路有關(guān)。
Abstract:
Objective To investigate whether soluble epoxide hydrolase inhibitors (t-AUCB) can promote the secretion of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α (HIF-1α) in murine endothelial progenitor cells (EPCs), and the possible related mechanisms.Methods Long bone marrow of mice was extracted and centrifugally cultured to obtain high purity EPCs．Different concentrations of soluble epoxide hydrolase inhibitor (t-AUB) and peroxide proliferator-activated receptor γ (PPAR-γ) blocker GW9662 were used to interfere with EPCs alone or in combination.The secretion of VEGF and HIF-1α in vitro of EPCs was detected by Western blot.Results From 0 to 100 μmol/L, t-AUCB enhanced the ability of EPCs to secrete VEGF and HIF-1α in a concentration dependent manner, while 5 μmol/L t-AUCB blocker GW9662 inhibited the above functions of EPCs.Compared with 0 μmol/L t-AUCB, 1, 10, 50 and 100 μmol/L t-AUCB promoted the secretion of VEGF and HIF-1α in EPCs, and the differences were statistically significant (P<0.05).The difference between GW9662+100 μmol/L t-AUCB and 100 μmol/L t-AUCB was statistically significant (P<0.05), compared with 0 μmol/L t-AUCB, the difference was also statistically significant (P<0.05).Conclusion t-AUCB can promote the secretion of VEGF and HIF-1α in EPCs, and the mechanism may be related to the activation of PPAR-γ pathway.

參考文獻(xiàn)/References:

[1]Zhang H F，Wang Y L，Tan Y Z，et al．Enhancement of cardiac lymphangiogenesis by transplantation of CD34 + VEGFR-3 + endothelial progenitor cells and sustained release of VEGF-C[J]．Basic Res Cardiol，2019，114（6）：43.
[2]Kamel N M，El-Fattah M A A，El-Abhar H S，et al．Novel repair mechanisms in a renal ischaemia/reperfusion model： Subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1/cAMP/VEGF，ANP/eNOS/NO，SDF-1α/CXCR4，and Kim-1/STAT3/HIF-1α/VEGF/eNOS pathways[J]．Eur J Pharmacol，2019，861：172620.
[3]Sheng Z Q，Li Y F，Zheng K L，et al．The relationship between number and function of EPCs and concentration of VEGF165 and SDF-1 in coronary artery spasm[J]．Eur Rev Med Pharmacol Sci，2018，22（9）：2767-2777.
[4]Qin Z Q，Li X，Yang J，et al．VEGF and Ang-1 promotes endothelial progenitor cells homing in the rat model of renal ischemia and reperfusion injury[J]．Int J Clin Exp Pathol，2017，10（12）：11896-11908.
[5]Ge Q H，Zhang H W，Hou J X，et al．VEGF secreted by mesenchymal stem cells mediates the differentiation of endothelial progenitor cells into endothelial cells via paracrine mechanisms[J]．Mol Med Rep，2018，17（1）：1667-1675.
[6]Chen S S，Tang C H，Chie M J，et al．Resistin facilitates VEGF-A-dependent angiogenesis by inhibiting miR-16-5p in human chondrosarcoma cells[J].Cell Death Dis，2019，10（1）：31.
[7]Choo S Y，Yoon S H，Lee D J，et al．Runx3 inhibits endothelial progenitor cell differentiation and function via suppression of HIF-1α activity[J]．Int J Oncol，2019，54（4）：1327-1336.
[8]Wang C X，Lin G，Luan Y，et al．HIF-prolyl hydroxylase 2 silencing using siRNA delivered by MRI-visible nanoparticles improves therapy efficacy of transplanted EPCs for ischemic stroke[J]．Biomaterials，2019，197：229-243.
[9]Cui F，Wang X L，Wang W，et al．Detection of AD-BMP-2-IRES-HIF-1α MU on local promoting angiogenic and osteogenic capacity of necrosis area[J]．Pak J Pharm Sci，2017，30（5（Supplementary））：2013-2019.
[10]Zhou W，Zhou W M，Zeng Q Z，et al．MicroRNA-138 inhibits hypoxia-induced proliferation of endothelial progenitor cells via inhibition of HIF-1α-mediated MAPK and AKT signaling[J]．Exp Ther Med，2017，13（3）：1017-1024.
[11]Guo Y，Luo F，Zhang X，et al．TPPU enhanced exercise-induced epoxyeicosatrienoic acid concentrations to exert cardioprotection in mice after myocardial infarction[J]．J Cell Mol Med，2018，22（3）：1489-1500.
[12]Rand A A，Rajamani A，Kodani S D，et al．Epoxyeicosatrienoic acid （EET）-stimulated angiogenesis is mediated by epoxy hydroxyeicosatrienoic acids（EHETs）formed from COX-2[J].J Lipid Res，2019，60（12）：1996-2005.
[13]Sommer K，Jakob H，Badjlan F，et al．11，12 and 14，15 epoxyeicosatrienoic acid rescue deteriorated wound healing in ischemia[J].PLoS One，2019，14（1）：e0209158.
[14]Maayah Z H，McGinn E，Al Batran R，et al．Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy[J].J Cardiovasc Pharmacol，2019，74（3）：235-245.
[15]ervenka L，Husková Z，Kopkan L，et al．Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin Ⅱ-dependent hypertension[J]．J Hypertens，2018，36（6）：1326-1341.
[16]Kala P，Sedláková L，karoupková P，et al．Effect of angiotensin-converting enzyme blockade,alone or combined with blockade of soluble epoxide hydrolase,on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula[J]．Physiol Res，2018，67（3）：401-415.
[17]Zhang W Y，Yang A L，Liao J，et al．Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice[J].Dig Dis Sci，2012，57（10）：2580-2591.
[18]Liu J Y，Yang J，Inceoglu B，et al．Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model[J]．Biochem Pharmacol，2010，79（6）：880-887.
[19]Inoue H，Hwang S H，Wecksler A T，et al．Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy[J].Cancer Biol Ther，2011，12（9）：827-836

備注/Memo

備注/Memo:
基金項(xiàng)目：福建省衛(wèi)生廳青年科研課題（2013-2-84）
1 中南大學(xué)湘雅二醫(yī)院心內(nèi)科（410011）
更新日期/Last Update: 2021-08-15